Insider Selling: Alto Neuroscience (NYSE:ANRO) CFO Sells 24,056 Shares of Stock

Alto Neuroscience, Inc. (NYSE:ANRO) CFO Nicholas Smith sold 24,056 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the sale, the chief financial officer owned 24,060 shares in the company, valued at approximately $621,229.20. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nicholas Conrad Smith also recently made the following trade(s):

• On Tuesday, September 29th, Nicholas Smith sold 110,830 shares of Alto Neuroscience stock. The shares were sold at an average price of $26.58, for a total value of $2,945,861.40.

Alto Neuroscience Trading Down 1.2%

ANRO traded down $0.31 during trading on Thursday, reaching $25.22. The company had a trading volume of 575,756 shares, compared to its average volume of 585,598. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The business has a 50 day simple moving average of $31.13 and a 200-day simple moving average of $26.15. The stock has a market cap of $989.48 million, a P/E ratio of -10.42 and a beta of 1.32. Alto Neuroscience, Inc. has a 52 week low of $4.04 and a 52 week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last announced its earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08. On average, equities analysts anticipate that Alto Neuroscience, Inc. will post -2.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. Wedbush upped their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research report on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. BTIG Research upped their price target on shares of Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wall Street Zen cut shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, Zacks Research raised shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Alto Neuroscience has an average rating of “Moderate Buy” and an average target price of $37.25.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. AWM Investment Company Inc. purchased a new stake in shares of Alto Neuroscience in the 2nd quarter worth $2,111,000. Jennison Associates LLC bought a new position in shares of Alto Neuroscience during the 1st quarter worth $8,687,000. Perceptive Advisors LLC increased its stake in shares of Alto Neuroscience by 12.6% during the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after buying an additional 225,500 shares during the period. Orbimed Advisors LLC increased its stake in shares of Alto Neuroscience by 34.0% during the first quarter. Orbimed Advisors LLC now owns 167,500 shares of the company’s stock valued at $3,765,000 after buying an additional 42,500 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in shares of Alto Neuroscience in the second quarter valued at about $2,014,000.

About Alto Neuroscience

Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with neuropsychiatric disorders. The company combines clinical data, biological measurements and digital assessments to identify patient characteristics that may help predict treatment response and guide the development of more targeted therapies.

Alto’s pipeline has included investigational treatments for conditions such as major depressive disorder and schizophrenia.